Literature DB >> 10761725

A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria.

M Van Vugt1, B J Angus, R N Price, C Mann, J A Simpson, C Poletto, S E Htoo, S Looareesuwan, N J White, F Nosten.   

Abstract

The artemisinin derivatives are now used widely in areas with multidrug-resistant Plasmodium falciparum malaria such as Southeast Asia, but concerns remain over their potential for neurotoxicity. Mice, rats, dogs, and monkeys treated with high doses of intramuscular artemether or arteether develop an unusual pattern of focal damage to brain stem nuclei (particularly those involved in auditory processing). To investigate whether a similar toxic effect occurs in patients treated with these compounds, clinical neurologic evaluation, audiometry and early latency auditory evoked responses were measured in a single-blind comparison of 79 patients who had been treated with > or =2 courses of oral artemether or artesunate within the previous 3 years, and 79 age- and sex-matched controls living in a malaria-endemic area on the northwestern border of Thailand. There were no consistent differences in any of these test results between the cases and controls. This study failed to detect any evidence of significant neurotoxicity in patients treated previously with oral artemether or artesunate for acute malaria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10761725     DOI: 10.4269/ajtmh.2000.62.65

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  16 in total

1.  Oral artesunate dose-response relationship in acute falciparum malaria.

Authors:  Brian J Angus; Itaporn Thaiaporn; Kenechanh Chanthapadith; Yupin Suputtamongkol; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.

Authors:  Gabriel Carrasquilla; Clemencia Barón; Edwin M Monsell; Marc Cousin; Verena Walter; Gilbert Lefèvre; Oliver Sander; Laurel M Fisher
Journal:  Am J Trop Med Hyg       Date:  2012-01       Impact factor: 2.345

Review 3.  Artemisinins.

Authors:  C J Woodrow; R K Haynes; S Krishna
Journal:  Postgrad Med J       Date:  2005-02       Impact factor: 2.401

4.  Recent Advances in the Prophylaxis and Treatment of Malaria.

Authors:  Annie-Claude Labbé; Mona R. Loutfy; Kevin C. Kain
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

Review 5.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 6.  Combination therapy for malaria: the way forward?

Authors:  François Nosten; Philippe Brasseur
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria.

Authors:  Timothy M E Davis; Tran Quang Binh; Kenneth F Ilett; Kevin T Batty; Hoang Lan Phuöng; Gregory M Chiswell; Vu Duong Bich Phuong; Cindy Agus
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

8.  Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa.

Authors:  Ushma Mehta; David Durrheim; Aaron Mabuza; Lucille Blumberg; Elizabeth Allen; Karen I Barnes
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria.

Authors:  Michael T Ambler; Lilly M Dubowitz; Ratree Arunjerdja; Eh Paw Hla; Kyaw Lay Thwai; Jacher Viladpainguen; Pratap Singhasivanon; Christine Luxemburger; François Nosten; Rose McGready
Journal:  Malar J       Date:  2009-09-02       Impact factor: 2.979

Review 10.  Safety profile of Coartem: the evidence base.

Authors:  Catherine Falade; Christine Manyando
Journal:  Malar J       Date:  2009-10-12       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.